natgillin/translations-raw huggingface dataset:
These occurred more frequently at higher dosages (1200-1500 mg/day) and in patients with advanced HIV disease (especially when there is poor bone marrow reserve prior to treatment), and particularly in patients with CD4 cell counts less than 100/mm3 (see section 4.4).
Pogosteje so se pojavile pri dajanju višjih odmerkov (1200 – 1500 mg/dan) in pri bolnikih v napredovalem obdobju bolezni (zlasti če so imeli že pred začetkom zdravljenja zmanjšano zalogo kostnega mozga), še posebej pa pri bolnikih, pri katerih je bilo število celic CD4 manjše od 100/mm3 (glejte poglavje 4.4).
These occurred more frequently at higher zidovudine doses (1200- 1500 mg/day) and in patients with poor bone marrow reserve prior to treatment, particularly with advanced HIV disease.
Te so se pogosteje pojavile pri višjih odmerkih zidovudina (1200 do 1500 mg/dan) in pri bolnikih, ki so že pred začetkom zdravljenja imeli zmanjšano zalogo kostnega mozga, še posebej pri tistih v napredovalem obdobju HIV bolezni.
These occurrences are generally self-limiting and of short duration.
Ti znaki navadno minejo sami od sebe in so kratkotrajni.
These packs will include information on the safety of the medicine and an alert card to be given to patients.
To bo vsebovalo informacije o varnosti zdravila in opozorilno kartico, namenjeno bolnikom.
These partial seizures may or may not then be followed by a fit affecting all of your brain (called a “secondary generalisation”).
Tem delnim napadom lahko sledi napad, ki prizadene cele možgane (imenovan „sekundarna generalizacija“).
These patient- observable differences were seen 8 weeks after initiating treatment.
Spremembe, ki so jih opazili bolniki, so se pojavile po 8 tednih zdravljenja.
These patient-reported outcomes were highly correlated to the clinician grading of oral mucositis using the WHO scale.
Ti samoopisani izidi so močno korelirali s klinično razvrstitvijo oralnega mukozitisa po lestvici SZO.
These patients are also at increased risk for sphincter of Oddi spasm (see section 4.4).
Tudi ti bolniki imajo zvečano tveganje za spazem Oddijevega sfinktra (glejte poglavje 4.4).
These patients are to be carefully monitored for signs and symptoms of bleeding complications and anaemia after initiation of treatment (see section 4.8).
Te bolnike je treba po uvedbi zdravljenja skrbno spremljati glede znakov in simptomov krvavitev in anemije.
These patients did not experience any adverse reactions that were not seen with the recommended dose.
Ti bolniki niso izkusili nobenih neželenih učinkov, ki niso bili opaženi s priporočenim odmerkom.
These patients discontinued at a higher rate due to intolerance (Grade 3 or 4 adverse events and serious adverse events), when compared to patients < 75 years (see section 4.4).
Ti bolniki so pogosteje prenehali z zdravljenjem zaradi intolerance (neželeni dogodki 3. ali 4. stopnje in resni neželeni dogodki) kot bolniki, mlajši od 75 let (glejte poglavje 4.4).
These patients discontinued at a higher rate due to intolerance (Grade 3 or 4 adverse events and serious adverse events), when compared to patients < 75 years. (see Section 4.4).
Ti bolniki so pogosteje prenehali z zdravljenjem zaradi intolerance (neželeni dogodki 3. ali 4. stopnje in resni neželeni dogodki) kot bolniki, mlajši od 75 let (glejte poglavje 4.4).
these patients dosing should be managed cautiously.
Pri teh bolnikih mora biti odmerjanje previdno.
These patients experienced more serious adverse events and adverse events leading to death than patients with a CrCl ≥50 mL/min (see section 4.2 and 5.2).
Ti bolniki so imeli več resnih neželenih dogodkov in neželenih dogodkov, ki so povzročili smrt, kot bolniki z očistkom kreatinina ≥ 50 ml/min (glejte poglavji 4.2 in 5.2).
These patients had a wide variety of complex underlying conditions such as haematological malignancies and HIV-infection or were transplant recipients and/or treated in intensive care.
Ti bolniki so imeli široko paleto sočasno prisotnih kompleksnih bolezni, kot so maligne krvne bolezni in okužbe s HIV, so bili prejemniki presadkov in/ali so se zdravili na oddelku intenzivne nege.
These patients had high disease activity as defined by elevated haemolysis (LDH ≥1.5x ULN) and the presence of related clinical symptom(s): fatigue, haemoglobinuria, abdominal pain, shortness of breath (dyspnoea), anaemia (haemoglobin <100 g/L), major adverse vascular event (including thrombosis), dysphagia, or erectile dysfunction.
Ti bolniki so imeli veliko aktivnost bolezni, kar je opredeljeno z zvečano hemolizo (LDH ≥1,5 x zgornja meja normale) in prisotnostjo povezanih kliničnih simptomov: utrujenost, hemoglobinurija, bolečine v trebuhu, kratka sapa (dispneja), anemija (hemoglobin <100 g/l), večji neželeni žilni dogodek (vključno s trombozo), disfagija ali erektilne motnje.
These patients have a shortage of the C1 inhibitor protein in their blood.
Tem bolnikom v krvi primanjkuje beljakovine, imenovane zaviralec C1.
These patients have an abnormal immune system (the body’s defence system) that needs to be adjusted.
Ti imajo nenormalen imunski sistem (obrambni sistem človeškega telesa), ki ga je treba uravnati.
These patients have limited treatment options and Darzalex, which works in a different way to existing treatments, represents an alternative.
Ti bolniki imajo omejene možnosti zdravljenja in zdravilo Darzalex, ki v primerjavi z obstoječimi zdravili deluje na drugačen način, predstavlja alternativno možnost zdravljenja.
These patients lived for an average of 11.2 months without their disease getting worse.
Ti bolniki so povprečno živeli 11,2 meseca brez poslabšanja bolezni.
These patients might be at risk of disease by uncommon serogroups (such as X), although meningococcal disease due to any serogroup may occur.
Pri teh bolnikih utegne obstajati tveganje za bolezen, pogojeno z manj pogostimi serološkimi skupinami (na primer X), čeprav je meningokokna bolezen možna zaradi katerekoli serološke skupine.
These patients must never be treated with medicinal products that suppress the peristalsis.
Takih pacientov nikoli ne smemo zdraviti z zdravili, ki zavirajo peristaltiko.
These patients received imatinib for a median of 47 months (range 24 days - 60 months).
Ti bolniki so prejemali imatinib mediano 47 mesecev (razpon 24 dni - 60 mesecev).
These patients received imatinib for a median of 47 months (range 24 days – 60 months).
Ti bolniki so prejemali imatinib mediano 47 mesecev (od 24 dni do 60 mesecev).
These patients received imatinib for a median of 47 months (range 24 days – 60 months).
Ti bolniki so prejemali zdravilo Imatinib Actavis mediano 47 mesecev (od 24 dni do 60 mesecev).
These patients received PREZISTA/ritonavir 800/100 mg once daily in combination with other antiretroviral agents.
Ti bolniki so prejeli zdravili PREZISTA/ritonavir 800/100 mg enkrat na dan v kombinaciji z drugimi protiretrovirusnimi zdravili.
These patients received PREZISTA/ritonavir twice daily in combination with other antiretroviral agents (see section 4.2 for dosage recommendations per body weight).
Ti bolniki so prejeli zdravili PREZISTA/ritonavir dvakrat na dan v kombinaciji z drugimi protiretrovirusnimi zdravili (priporočila za odmerjanje glede na telesno maso so navedena v poglavju 4.2).
These patients should be carefully monitored for clinical signs and symptoms of CHF while receiving sunitinib.
Takšne bolnike je treba med zdravljenjem s sunitinibom skrbno spremljati glede kliničnih znakov in simptomov kongestivnega srčnega popuščanja.
These patients should be followed closely.
Takšne bolnike je treba natančno spremljati.
These patients should be followed closely.
Te bolnike je treba pazljivo spremljati.
These patients should be monitored for signs and symptoms of active HBV infection throughout therapy and for several weeks following termination of therapy.
Take bolnike je treba ves čas zdravljenja in še več tednov po prekinitvi zdravljenja spremljati glede znakov in simptomov aktivne okužbe s HBV.
These patients should be monitored for signs and symptoms of active HBV infection throughout therapy and for several weeks following termination of therapy.
Takšne bolnike je treba ves čas zdravljenja in še več tednov po prekinitvi zdravljenja spremljati glede znakov in simptomov aktivne okužbe s HBV.
These patients should be observed carefully for signs and symptoms of thromboembolism.
Te bolnike je treba natančno nadzirati glede pojava znakov in simptomov trombembolije.
These patients should be started at a lower dose which should be given every other day.
Pri teh bolnikih je treba zdravljenje začeti z nižjim odmerkom, ki se daje vsak drugi dan.
These patients should be treated with caution.
Te bolnike je treba previdno zdraviti.
These patients should be very closely monitored throughout the first infusion.
Med celotnim trajanjem prve infuzije jih je treba natančno opazovati.
These patients should no longer be treated with any asparaginase preparation (see also sections 4.3 and 4.8).
Ti bolniki se ne smejo več zdraviti z nobenim zdravilom z asparaginazo (glejte tudi poglavji 4.3 in 4.8).
These patients should therefore be treated carefully.
Zato je pri teh bolnikih potrebna posebna previdnost.
These patients were compared with a ‘historical comparison group’ of babies and young children with Pompe disease who had not received treatment and did not take part in the studies.
Te bolnike so primerjali s historično primerjalno skupino dojenčkov in otrok s Pompejevo boleznijo, ki niso bili zdravljeni in niso sodelovali v študijah.
These patients were either newly diagnosed, Ph+ chronic phase CML or were resistant or intolerant to prior therapy with Ph+ chronic, accelerated, or blast phase CML or Ph+ acute lymphoblastic leukaemia (ALL).
Tem bolnikom so bodisi na novo odkrili Ph+ KML v kronični fazi bodisi so bili neodzivni ali niso prenašali predhodnega zdravljenja Ph+ KML v kronični, pospešeni ali blastni fazi ali Ph+ akutne limfoblastne levkemije (ALL).
These patients, who generally have poor prognosis, experienced an overall delay of 6.9 months in the progression of their disease, which might allow the next cycle of platinum-based chemotherapy to be delayed.
Pri teh bolnicah, ki imajo na splošno slabo napoved, je bolezen napredovala celokupno 6,9 meseca kasneje, kar lahko omogoči zamik naslednjega cikla kemoterapije na osnovi platine.
These peaks were followed by a biphasic elimination profile consisting of an initial sharp decline and subsequent slow decline with a terminal phase half-life of 100 to 263 hours over a dose-range of 12.5 mg to 75 mg.
Tem vrhom je sledil dvofazni profil eliminacije, sestavljen iz začetnega hitrega padca, ki mu sledi počasen padec z razpolovnim časom terminalne faze od 100 do 263 ur pri odmerkih od 12,5 mg do 75 mg.
These pens are only for one person.
Ta peresnika sta namenjena le za uporabo pri eni sami osebi.
These persons will take special care for the safe use of this product and will keep you informed of their actions.
Ti bodo zlasti pozorni na varno uporabo zdravila in vas bodo sproti obveščali o svojem ravnanju.
These pharmacodynamic effects of prucalopride have been confirmed in human subjects with chronic constipation using manometry in an open-label, randomised, crossover, reader-blinded study investigating the effect of prucalopride 2mg and an osmotic laxative on colon motility as determined by the number of colonic high-amplitude propagating contractions (HAPCs, also known as giant migrating contractions).
Ti farmakodinamični učinki prukaloprida so bili pri ljudeh s kronično zaprtostjo potrjeni z manometrom v odprti, randomizirani, navzkrižni, za ocenjevalce slepi študiji, v kateri so preučevali učinek prukaloprida v odmerku 2 mg in osmotskega odvajala na gibljivost debelega črevesa, opredeljeno s številom kontrakcij debelega črevesa visoke amplitude (HAPC – high-amplitude propagating contractions, ki se imenujejo tudi velike seleče se kontrakcije).
These pharmacologically- mediated undesirable effects, known from preclinical studies with both angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists, were prevented by oral saline supplementation.
Te farmakološke neželene učinke, ki so jih odkrile predklinične študije tako pri zaviralcih ACE kot antagonistih receptorjev angiotenzina II, so preprečili s peroralnim dajanjem solne raztopine.
These pharmacologically- mediated undesirable effects, known from preclinical studies with both angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists, were prevented by oral saline supplementation.
Te farmakološke neželene učinke, ki so jih odkrile predklinične študije tako pri zaviralcih angiotenzinske konvertaze kot antagonistih receptorjev angiotenzina II, so preprečili s peroralnim dajanjem fiziološke raztopine.
These pharmacologically- mediated undesirable effects, known from preclinical studies with both angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists, were prevented by oral saline supplementation.
Te farmakološke neželene učinke, ki so jih odkrile predklinične študije tako pri zaviralcih angiotenzinske konvertaze kot antagonistih receptorjev angiotenzina II, so preprečili s peroralnim dajanjem solne raztopine.
These pharmacologically- mediated undesirable effects, known from preclinical studies with both angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists, were prevented by oral saline supplementation.
Te farmakološko posredovane neželene učinke, ki so znani iz predkliničnih študij zaviralcev angiotenzinske konvertaze in antagonistov receptorjev angiotenzina II, je bilo mogoče preprečiti s peroralnim dodajanjem raztopine soli.
These platelet changes were not present in rats or in humans based on short term and limited long-term clinical data.
Kot kažejo podatki kratkotrajnih in omejeni podatki dolgotrajnih študij, te spremembe trombocitov niso prisotne pri podganah niti pri ljudeh.
These platelet changes were not present in rats or in humans based on short-term and limited long- term clinical data.
Kot kažejo podatki kratkotrajnih in omejeni podatki dolgotrajnih študij, te spremembe trombocitov niso prisotne pri podganah niti pri ljudeh.
These points should be considered when initiating pramipexole treatment in patients with Parkinson’s disease.
Naštete izsledke je treba upoštevati ob uvajanju zdravljenja s pramipeksolom pri bolnikih s Parkinsonovo boleznijo.
These points should be considered when initiating pramipexole treatment in patients with Parkinson’s disease.
Našteto morate upoštevati, ko pri bolnikih s Parkinsonovo boleznijo uvajate zdravljenje s pramipeksolom.
These polysaccharides have been purified, then ‘conjugated’ (attached) to a carrier to help them be better recognised by the immune system.
Te polisaharide se prečisti, nato „konjugira“ (veže) na nosilec, zaradi česar jih imunski sistem lahko bolje prepozna.
These polysaccharides have been purified, then ‘conjugated’ (attached) to a carrier to help them to be recognised by the immune system.
Ti polisaharidi se prečistijo in nato konjugirajo (vežejo) na nosilec, zaradi česar jih imunski sistem lahko prepozna.
These polysaccharides have been purified, then ‘conjugated’ (attached) to a carrier to help them to be recognised by the immune system.
Ti polisaharidi se prečistijo in nato „konjugirajo“ (vežejo) na nosilec, zaradi česar jih imunski sistem lahko prepozna.
these possible side effects when using PDE5 inhibitors for erectile dysfunction with EVOTAZ (see section 4.4).
možne neželene učinke pri uporabi zaviralcev PDE5 za zdravljenje erektilne disfunkcije, če se jih uporablja skupaj z zdravilom EVOTAZ (glejte poglavje 4.4).
These proportions were maintained at week 100 with 76.8 % (n = 76) in the Eylea group and 78% (n = 39) in the sham group.
Ta delež se je ohranil do 100. tedna s 76,8 % (N = 76) v skupini, ki je prejemala zdravilo Eylea in 78 % (N = 39) v skupini, ki je prejemala placebo.
These proteins can be present in high amounts in cancer cells, and by blocking their action CABOMETYX can slow down the rate at which the tumour grows and help to cut off the blood supply that the cancer needs.
Te beljakovine so lahko v rakavih celicah prisotne v velikih količinah, zato lahko zdravilo CABOMETYX z zavrtjem upočasni hitrost rasti tumorja in pomaga prekiniti oskrbo krvi, ki jo potrebuje rak.
These protocol mandated clinical sign assessments indicate that local skin reactions including erythema (61%), erosion (30%), excoriation/flaking/scaling (23%) and oedema (14%) were common in these placebo controlled clinical trials with imiquimod cream applied three times weekly (see section 4.4).
Ta predpisana vrednotenja kliničnih znakov so pokazala, da so bile lokalne reakcije na koži, vključno z rdečico (61%), erozijo (30%), lupljenjem/luskavostjo (23%) in oteklino (14%), pogoste v teh s placebom nadzorovanih preskušanjih, kjer je bila imikvimod krema nanešena trikrat tedensko (glejte poglavje 4.4).
These protocol mandated clinical sign assessments indicate that severe erythema (31%) severe erosions (13%) and severe scabbing and crusting (19%) were very common in these trials with imiquimod cream applied 5 times weekly.
Vrednotenje v protokolu navedenih kliničnih znakov je pokazalo, da so bile huda rdečica (31%), huda erozija (13%) in huda luskavost ter tvorba krast (19%) zelo pogoste v teh preskušanjih, kjer je bila imikvimod krema nanešena petkrat tedensko.
These protonated amines bind negatively charged ions such as dietary phosphate in the intestine.
Ti protonirani amini vežejo ione z negativnim nabojem kot si dietni fosfati v črevesju.
These pulmonary adverse reactions may also include pulmonary oedema, pulmonary infiltrates, pulmonary fibrosis, respiratory failure or ARDS (see section 4.4).
Ti neželeni učinki na pljuča lahko vključujejo tudi pljučni edem, pljučne infiltrate, pljučno fibrozo, dihalno odpoved ali ARDS (glejte poglavje 4.4).
These reactions abated after dose reduction and are suggestive of overdose.
Ti reakciji sta izzveneli po zmanjšanju odmerka in kažeta na možnost prevelikega odmerjanja.
These reactions are generally of a transitory nature and are reversible when the treatment is stopped.
Te reakcije so navadno prehodne in minejo, ko prenehamo z zdravljenjem.
These reactions are generally temporary and reversible when the treatment is stopped.
Ti učinki so navadno začasni in minejo ob prenehanju jemanja zdravila.
These reactions are more likely to happen on the day of, or day after, your first or second treatment with Benlysta.
Te reakcije so verjetnejše na dan, ko zdravilo Benlysta prejmete prvič ali drugič, ali dan pozneje.
These reactions are often transitory.
Ti neželeni učinku so pogosto prehodni.
These reactions are seen rarely (may affect up to 1 in 1,000 people).
Te reakcije so sicer redke (pojavijo se lahko pri največ 1 od 1.000 bolnikov).
These reactions are usually of transitory nature.
Te reakcije so običajno prehodne.
These reactions are usually of transitory nature.
Te reakcije so ponavadi prehodne narave.
These reactions are very common (may affect more than 1 in 10 people)
Te reakcije so zelo pogoste (pojavijo se lahko pri več kot 1 od 10 bolnikov)
These reactions can appear in the first week of treatment and usually only last for up to 7 days.
Te reakcije se lahko pojavijo v prvem tednu zdravljenja in običajno trajajo 7 dni ali manj.
These reactions generally occur within hours of administration, but in some instances have a delayed onset (i.e., typically within several days).
Po navadi se te reakcije pojavijo v nekaj urah po uporabi, v nekaterih primerih pa se lahko pojavijo pozno (tj. tipično v nekaj dneh).
These reactions have been reported mainly from post-marketing experience with DepoCyte as spontaneous case reports.
O teh učinkih so poročali predvsem po začetku trženja zdravila DepoCyte v obliki spontano prijavljenih primerov.
These reactions have included altered mental states including severe somnolence, central nervous system effects including convulsions, and peripheral neuropathy ranging from numbness and paresthesias to motor weakness and paralysis.
Ti učinki so vključevali spremembe duševnega stanja, vključno s hudo somnolenco, učinke na centralni živčni sistem, vključno s konvulzijami, ter periferno nevropatijo, v razponu od odrevenelosti in parestezije do motorične oslabelosti in paralize.
These reactions have resulted in varying degrees of neurologic injuries including long term or permanent paralysis (see section 4.4)
To je vodilo v različne stopnje nevroloških okvar, vključno z dolgotrajno ali trajno paralizo (glejte poglavje 4.4).
These reactions include;
Te reakcije vključujejo:
These reactions may be common (they can affect up to 1 in 10 people).
Te reakcije so lahko pogoste (pojavijo se lahko pri do 1 od 10 oseb).
These reactions may occur for the first time after a long duration of treatment (see section 4.8).
Te reakcije se lahko prvič pojavijo po že dolgotrajnem zdravljenju (glejte poglavje 4.8).
These reactions resolve spontaneously in maximum 4 days in average without any consequence on the health and the zootechnical performances.
Reakcije v povprečju spontano preidejo v največ 4 dneh brez posledic za zdravje in zootehnične rezultate.
These reactions resolve spontaneously over a period of approximately 14–21 days without any major consequence on the general health status of the animals.
Te reakcije po približno 14 do 21 dneh minejo brez večjih posledic za splošno zdravstveno stanje živali.
These reactions resolve spontaneously, in a maximum of 4 days on average, without any consequence on the health and the zootechnical performance.
Reakcije v povprečju spontano preidejo v največ 4 dneh brez posledic za zdravje in zootehnične rezultate.
These reactions should disappear within 2-3 days.
Ta reakcija lahko traja največ 2 do 3 dni.
These reactions start within 24-72 hours after vaccination, may be associated with erythema, warmth, tenderness or pain at the injection site and resolve spontaneously within 3-5 days.
Te reakcije se pojavijo v 24–72 urah po cepljenju, lahko so povezane z pordelostjo, toploto, občutljivostjo ali bolečino na mestu injiciranja in minejo spontano v 3–5 dneh.
These reactions start within 24-72 hours after vaccination, may be associated with redness, warmth, tenderness or pain at the injection site, and get better within 3-5 days without the need for treatment. fits (convulsions) with or without fever
Te reakcije se pojavijo v 24–72 urah po cepljenju, lahko so povezane s pordelostjo, toploto, občutljivostjo ali bolečino na mestu injiciranja in se izboljšajo v 3–5 dneh brez potrebe po zdravljenju krči (konvulzije) z zvišano telesno temperaturo ali brez nje.
These reactions start within 24-72 hours after vaccination, may be associated with redness, warmth, tenderness or pain at the injection site, and get better within 3-5 days without the need for treatment. fits (convulsions) with or without fever
Te reakcije se pojavijo v 24–72 urah po cepljenju, lahko so povezane s pordelostjo, toploto, občutljivostjo ali bolečino na mestu injiciranja in se izboljšajo v 3–5 dneh brez potrebe po zdravljenju. krči (konvulzije) z zvišano telesno temperaturo ali brez nje
These reactions start within 24-72 hours after vaccination, may be associated with redness, warmth, tenderness or pain at the injection site, and get better within 3-5 days without the need for treatment. fits (convulsions) with or without fever.
Te reakcije se pojavijo v 24–72 urah po cepljenju, lahko so povezane s pordelostjo, toploto, občutljivostjo ali bolečino na mestu injiciranja in se izboljšajo v 3–5 dneh brez potrebe po zdravljenju krči (konvulzije) z zvišano telesno temperaturo ali brez nje.
These reactions take the form in most cases of a general swelling of the injection site (persisting for not more than 7 days) or of palpable nodules (subcutaneous granuloma possibly persisting for more than 48 days).
Te reakcije so v večini primerov v obliki splošne otekline na mestu injiciranja (ne traja več kot 7 dni) ali kot otipljivi noduli (subkutani granulomi, ki lahko trajajo tudi več kot 48 dni).